A startup created as a spinoff of Myostratum to combine the intellectual property of Myostratum with that of the New Zealand-based company Kerablast. The goal of this company is to develop a keratin-based material that can be delivered via coronary injection to alter the material properties of myocardial infarction to prevent ventricular remodeling and heart failure.